Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Zeitschrift für Gerontologie und Geriatrie 5/2013

01.07.2013 | CME Zertifizierte Fortbildung

Digitalis und Theophyllin

Alt und entbehrlich?

verfasst von: M. Gosch, Dr. P. Dovjak

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Digitalis und Theophyllin gehören zu den ältesten Medikamenten in der Behandlung von Herz-Lungen-Erkrankungen. Trotz der langen Tradition ist die Evidenz widersprüchlich, teils eher negativ. Besonders groß ist das Spannungsfeld in der Geriatrie. Einerseits haben beide Substanzen noch einen Stellenwert, insbesondere in fortgeschrittenen Stadien der Erkrankungen bzw. als symptomatische Therapie, andererseits werden sie auf Listen als potenziell ungeeignete Medikamente für den älteren Patienten geführt. Der vorliegende Beitrag beleuchtet die aktuelle Datenlage zu beiden Substanzen auf Basis der aktuellen Literatur.
Literatur
1.
Zurück zum Zitat Ritz E, Schoner W (2008) From Digitalis purpurea to toad skin. An historical view of digitalis-like mammalian hormones. Dtsch Med Wochenschr 133(51–52):2690–2694. DOI 10.1055/s-0028-1105877 Ritz E, Schoner W (2008) From Digitalis purpurea to toad skin. An historical view of digitalis-like mammalian hormones. Dtsch Med Wochenschr 133(51–52):2690–2694. DOI 10.1055/s-0028-1105877
2.
Zurück zum Zitat Jelliffe RW (2012) Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy. Ther Drug Monit 34(4):368–377 PubMedCrossRef Jelliffe RW (2012) Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy. Ther Drug Monit 34(4):368–377 PubMedCrossRef
3.
Zurück zum Zitat Silverman ME (1989) William Withering and an account of the foxglove. Clin Cardiol 12(7):415–418 PubMedCrossRef Silverman ME (1989) William Withering and an account of the foxglove. Clin Cardiol 12(7):415–418 PubMedCrossRef
4.
Zurück zum Zitat Grosse-Brockhoff F, Hausamen TU (1975) 200 years heart therapy digitalis. William Withering and the 1st century of digitalis therapy. Dtsch Med Wochenschr 100(39):1980–1991 PubMedCrossRef Grosse-Brockhoff F, Hausamen TU (1975) 200 years heart therapy digitalis. William Withering and the 1st century of digitalis therapy. Dtsch Med Wochenschr 100(39):1980–1991 PubMedCrossRef
5.
Zurück zum Zitat Meyer KF (1974) Claude-Adolphe Nativelle. Pharmacist discovers digitaline. J Am Pharm Assoc 14(7):358–360 PubMed Meyer KF (1974) Claude-Adolphe Nativelle. Pharmacist discovers digitaline. J Am Pharm Assoc 14(7):358–360 PubMed
6.
Zurück zum Zitat Minkowski O (1902) Über Theocin (Theophyllin) als Diureticum. Ther Gegenwart 43:490–493 Minkowski O (1902) Über Theocin (Theophyllin) als Diureticum. Ther Gegenwart 43:490–493
7.
Zurück zum Zitat Schultze-Werninghaus G, Meier-Sydow J (1982) The clinical and pharmacological history of theophylline: first report on the bronchospasmolytic action in man by S.R. Hirsch in Frankfurt (Main) 1922. Clin Allergy 12:211–215 PubMedCrossRef Schultze-Werninghaus G, Meier-Sydow J (1982) The clinical and pharmacological history of theophylline: first report on the bronchospasmolytic action in man by S.R. Hirsch in Frankfurt (Main) 1922. Clin Allergy 12:211–215 PubMedCrossRef
8.
9.
Zurück zum Zitat Ferguson DW, Berg WJ, Sanders JS et al (1989) Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation 80(1):65–77 PubMedCrossRef Ferguson DW, Berg WJ, Sanders JS et al (1989) Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation 80(1):65–77 PubMedCrossRef
10.
Zurück zum Zitat Rabe KF, Magnussen H, Dent G (1995) Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur Respir J 8(4):637–642 PubMed Rabe KF, Magnussen H, Dent G (1995) Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur Respir J 8(4):637–642 PubMed
11.
Zurück zum Zitat Polson JB, Krzanowski JJ, Goldman AL, Szentivanyi A (1978) Inhibition of human pulmonary phosphodiesterase activity by therapeutic levels of theophylline. Clin Exp Pharmacol Physiol 5(5):535–539 PubMedCrossRef Polson JB, Krzanowski JJ, Goldman AL, Szentivanyi A (1978) Inhibition of human pulmonary phosphodiesterase activity by therapeutic levels of theophylline. Clin Exp Pharmacol Physiol 5(5):535–539 PubMedCrossRef
12.
Zurück zum Zitat Björck T, Gustafsson LE, Dahlén SE (1992) Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. Am Rev Respir Dis 145(5):1087–1091 PubMedCrossRef Björck T, Gustafsson LE, Dahlén SE (1992) Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. Am Rev Respir Dis 145(5):1087–1091 PubMedCrossRef
13.
Zurück zum Zitat Ito K, Caramori G, Lim S et al (2002) Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med 166(3):392–396 PubMedCrossRef Ito K, Caramori G, Lim S et al (2002) Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med 166(3):392–396 PubMedCrossRef
14.
Zurück zum Zitat Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of a trial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369–2429 PubMedCrossRef Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of a trial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369–2429 PubMedCrossRef
15.
Zurück zum Zitat Veldhuisen DJ van, Van Gelder IC, Ahmed A, Gheorghiade M (2013) Digoxin for patients with atrial fibrillation and heart failure: paradise lost or not? Eur Heart J (E-pub ahead of print) Veldhuisen DJ van, Van Gelder IC, Ahmed A, Gheorghiade M (2013) Digoxin for patients with atrial fibrillation and heart failure: paradise lost or not? Eur Heart J (E-pub ahead of print)
16.
Zurück zum Zitat Gosch M, Roller RE, Böhmdorfer B et al (2012) Management and therapy of atrial fibrillation in geriatric patients. Z Gerontol Geriatr 45(1):55–66 PubMedCrossRef Gosch M, Roller RE, Böhmdorfer B et al (2012) Management and therapy of atrial fibrillation in geriatric patients. Z Gerontol Geriatr 45(1):55–66 PubMedCrossRef
17.
Zurück zum Zitat Wyse DG, Waldo AL, DiMarco JP et al (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347(23):1825–1833 PubMedCrossRef Wyse DG, Waldo AL, DiMarco JP et al (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347(23):1825–1833 PubMedCrossRef
18.
Zurück zum Zitat Packer M, Gheorghiade M, Young JB et al (1993) Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 329(1):1–7 PubMedCrossRef Packer M, Gheorghiade M, Young JB et al (1993) Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 329(1):1–7 PubMedCrossRef
19.
Zurück zum Zitat The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336(8):525–533 CrossRef The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336(8):525–533 CrossRef
20.
Zurück zum Zitat Rathore SS, Curtis JP, Wang Y et al (2003) Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289(7):871–878 PubMedCrossRef Rathore SS, Curtis JP, Wang Y et al (2003) Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289(7):871–878 PubMedCrossRef
21.
Zurück zum Zitat Rathore SS, Wang Y, Krumholz HM (2002) Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347(18):1403–1411 PubMedCrossRef Rathore SS, Wang Y, Krumholz HM (2002) Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347(18):1403–1411 PubMedCrossRef
22.
Zurück zum Zitat Ather S, Peterson LE, Divakaran VG et al (2011) Digoxin treatment in heart failure – unveiling risk by cluster analysis of DIG data. Int J Cardiol 150(3):264–269. DOI 10.1016/j.ijcard.2010.04.021 PubMedCrossRef Ather S, Peterson LE, Divakaran VG et al (2011) Digoxin treatment in heart failure – unveiling risk by cluster analysis of DIG data. Int J Cardiol 150(3):264–269. DOI 10.1016/j.ijcard.2010.04.021 PubMedCrossRef
23.
Zurück zum Zitat Dovjak P (2013) Diastolic heart failure: heart failure with preserved ejection fraction. Z Gerontol Geriatr 46(1):71–81 PubMedCrossRef Dovjak P (2013) Diastolic heart failure: heart failure with preserved ejection fraction. Z Gerontol Geriatr 46(1):71–81 PubMedCrossRef
24.
Zurück zum Zitat Ahmed A, Rich MW, Fleg JL et al (2006) Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 114(5):397–403 PubMedCrossRef Ahmed A, Rich MW, Fleg JL et al (2006) Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 114(5):397–403 PubMedCrossRef
25.
Zurück zum Zitat McMurray JJ, Adamopoulos S, Anker SD et al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33(14):1787–1847 PubMedCrossRef McMurray JJ, Adamopoulos S, Anker SD et al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33(14):1787–1847 PubMedCrossRef
26.
Zurück zum Zitat Gheorghiade M, Patel K, Filippatos G et al (2013) Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail 15(5):551–559 PubMedCrossRef Gheorghiade M, Patel K, Filippatos G et al (2013) Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail 15(5):551–559 PubMedCrossRef
27.
Zurück zum Zitat Gheorghiade M, Hall V, Lakier JB, Goldstein S (1989) Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol 13(1):134–142 PubMedCrossRef Gheorghiade M, Hall V, Lakier JB, Goldstein S (1989) Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol 13(1):134–142 PubMedCrossRef
28.
Zurück zum Zitat The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group (1997) Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. Eur Heart J 18(4):649–654 CrossRef The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group (1997) Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. Eur Heart J 18(4):649–654 CrossRef
29.
Zurück zum Zitat BÄK, KBV, AWMF (2012) Nationale VersorgungsLeitlinie COPD. http://​www.​awmf.​org/​uploads/​tx_​szleitlinien/​nvl-003l_​S3_​COPD_​abgelaufen.​pdf BÄK, KBV, AWMF (2012) Nationale VersorgungsLeitlinie COPD. http://​www.​awmf.​org/​uploads/​tx_​szleitlinien/​nvl-003l_​S3_​COPD_​abgelaufen.​pdf
30.
Zurück zum Zitat Kardos P, Vogelmeier C, Worth H (2012) The new GOLD document. Pneumologie 66(8):493–496. DOI 10.1055/s-0032-1310053 PubMedCrossRef Kardos P, Vogelmeier C, Worth H (2012) The new GOLD document. Pneumologie 66(8):493–496. DOI 10.1055/s-0032-1310053 PubMedCrossRef
31.
Zurück zum Zitat Gayan-Ramirez G, Janssens S, Himpens B, Decramer M (1995) Mechanism of theophylline-induced inotropic effects on foreshortened canine diaphragm. Eur Respir J 8(11):1915–1921 PubMedCrossRef Gayan-Ramirez G, Janssens S, Himpens B, Decramer M (1995) Mechanism of theophylline-induced inotropic effects on foreshortened canine diaphragm. Eur Respir J 8(11):1915–1921 PubMedCrossRef
32.
Zurück zum Zitat Friege B, Friege L, Pelz J et al (2009) Bronchial asthma and chronic obstructive pulmonary disease with acute exacerbation: preclinical differential diagnostic and emergency treatment. Anaesthesist 58(6):611–622 PubMedCrossRef Friege B, Friege L, Pelz J et al (2009) Bronchial asthma and chronic obstructive pulmonary disease with acute exacerbation: preclinical differential diagnostic and emergency treatment. Anaesthesist 58(6):611–622 PubMedCrossRef
33.
Zurück zum Zitat Fick DM, Semla TP (2012) 2012 American Geriatrics Society Beers Criteria: new year, new criteria, new perspective. J Am Geriatr Soc 60(4):614–615. DOI 10.1111/j.1532-5415.2012.03922.x PubMedCrossRef Fick DM, Semla TP (2012) 2012 American Geriatrics Society Beers Criteria: new year, new criteria, new perspective. J Am Geriatr Soc 60(4):614–615. DOI 10.1111/j.1532-5415.2012.03922.x PubMedCrossRef
34.
Zurück zum Zitat Gallagher P, Ryan C, Byrne S et al (2008) STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther 46(2):72–83 PubMed Gallagher P, Ryan C, Byrne S et al (2008) STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther 46(2):72–83 PubMed
35.
Zurück zum Zitat Holt S, Schmiedl S, Thürmann PA (2010) Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int 107(31–32):543–551 Holt S, Schmiedl S, Thürmann PA (2010) Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int 107(31–32):543–551
36.
Zurück zum Zitat Wehling M (2008) Drug therapy in the elderly: too much or too little, what to do? A new assessment system: fit for the aged (FORTA). Dtsch Med Wochenschr 133(44):2289–2291 PubMedCrossRef Wehling M (2008) Drug therapy in the elderly: too much or too little, what to do? A new assessment system: fit for the aged (FORTA). Dtsch Med Wochenschr 133(44):2289–2291 PubMedCrossRef
37.
Zurück zum Zitat Mann E, Böhmdorfer B, Frühwald T et al (2012) Potentially inappropriate medication in geriatric patients: the Austrian consensus panel list. Wien Klin Wochenschr 124(5–6):160–169 Mann E, Böhmdorfer B, Frühwald T et al (2012) Potentially inappropriate medication in geriatric patients: the Austrian consensus panel list. Wien Klin Wochenschr 124(5–6):160–169
Metadaten
Titel
Digitalis und Theophyllin
Alt und entbehrlich?
verfasst von
M. Gosch
Dr. P. Dovjak
Publikationsdatum
01.07.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Zeitschrift für Gerontologie und Geriatrie / Ausgabe 5/2013
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI
https://doi.org/10.1007/s00391-013-0497-5